Benzinga | Dec 9, 2021 09:48PM EST

Ambrx Biopharma Inc. Presents Data From Ongoing ACE-Breast-01 Phase 1 Clinical Study Of ARX788 At San Antonio Breast Cancer Symposium; Co. Reports 'ARX788 demonstrated robust anti-tumor activity, with disease control rate of 100% in the 29 patients'

- ARX788 demonstrated robust anti-tumor activity, with disease control rate of 100% in the 29 patients treated at 1.5 mg/kg Q3W --

- ARX788 demonstrated treatment effect among patients who previously failed a median of seven anti-HER2 targeting therapies --

- Conducted a poster presentation of the ARX788 clinical study ACE-Breast-03 during an ongoing trial poster session at SABCS -